Day: June 4, 2024

Tealium’s Digital Velocity conferences return globally

The 10th annual flagship conference is hosted in San Diego, London, and Sydney, bringing together customers and partners from around the world San Diego, June 04, 2024 (GLOBE NEWSWIRE) —  Tealium, the largest independent and most trusted customer data platform (CDP), is hosting three flagship Digital Velocity conferences in-person for customers and partners in North […]

The 10th annual flagship conference is hosted in San Diego, London, and Sydney, bringing together customers and partners from around the world

San Diego, June 04, 2024 (GLOBE NEWSWIRE) —  Tealium, the largest independent and most trusted customer data platform (CDP), is hosting three flagship Digital Velocity conferences in-person for customers and partners in North America, Europe, and Asia Pacific regions. This year’s theme, Welcome to the Real-Time Revolution: Where Moments Matter, will showcase how customer data can be used to enhance business and customer experience results, specifically in the areas of AI, privacy, and compliance.

“The experience economy is undergoing major shifts driven by the acceleration of AI and evolving global privacy regulations,” said Jeff Lunsford, CEO of Tealium. “Tealium’s real-time platform helps brands take customer experience initiatives to new heights. We enable companies to dazzle customers during their most pivotal moments through data-driven personalization and seamless digital experiences that prioritize trust and respect for consumer privacy. This year at Digital Velocity, we will be deep-diving into how we make that possible for the enterprises we serve globally, featuring use cases directly from our customers.”

Below are the schedules for Tealium’s 2024 Digital Velocity conferences:

This year, Tealium announces strategic investments in several areas as part of its commitment to innovation:

  • The Tealium Trust Platform: Tealium’s standardized and governed infrastructure for real-time data applications and increased observability to orchestrate compliant customer data flows. This is a culmination of advancements to Tealium’s user interface (UI), embedded analytics, integration marketplace, and more.
  • Real-Time Data: The Tealium Moments API and Tealium Moments IQ are just the start of the company’s zero- and first-party real-time data solutions. These features provide real-time insights in new and more flexible ways to own the moments that matter most.
  • Artificial Intelligence: Data readiness is the foundation for AI success. Tealium is investing heavily in existing and new AI-powered solutions for more intelligent insights.
    • Tealium Predict: DIY-style, machine learning technology for enhanced customer experience initiatives.
    • Tealium Genius: New AI assistant to boost productivity and support teams in better understanding their data layer.
    • Tealium for AI: Fuel AI models with consented, filtered, and enriched data in real-time.
  • Expanded Partnerships: Embrace stack composability to leverage customers’ existing and new partner integrations for a more centralized infrastructure.
    • Tealium’s Cloud Data Warehouse Partner Ecosystem: A collection of integrations to work in harmony with cloud data providers, like Snowflake.
    • Global Ad Partner Expansion: New integration capabilities to accelerate ad performance and measurement with Snap, Pinterest, LinkedIn, The Trade Desk, Reddit, and more.

Tealium is also continuing to innovate within highly-regulated industries and has now launched Tealium for Healthcare. This new suite of solutions supports healthcare companies in reimagining the patient experience, all while prioritizing HIPAA compliance. The solution includes the following features: consent management, identity resolution for unified customer views, and secure data routing to protect PHI across the entire customer journey, among others.

To learn more and register for a Digital Velocity event in your region, visit tealium.com/events.

To keep up with the latest company news, visit Tealium’s Newsroom.

About Tealium
As the most trusted CDP, Tealium connects data so businesses can better connect with their customers. Tealium’s real-time data infrastructure allows brands to power their AI models and activate data for enhanced in-the-moment experiences. Tealium’s turnkey integration ecosystem supports more than 1,300 built-in connections from the world’s most prominent technology experts. Tealium’s solutions include a real-time customer data platform with machine learning, tag management, an API hub, and data management solutions that make customer data more valuable, actionable, privacy-compliant, and secure. Named as a Leader in the Gartner® Magic Quadrant for Customer Data Platforms™, more than 850 leading businesses globally trust Tealium to power their customer data strategies. For more information, visit www.tealium.com.

Natalie Passarelli
Tealium Inc. 
3129650210
natalie.passarelli@tealium.com

GlobeNewswire Distribution ID 9148412

Fortrea Completes Divestiture of Endpoint Clinical and Patient Access Businesses to Arsenal Capital Partners

DURHAM, N.C., June 04, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) a leading global contract research organization (“CRO”), today announced it has completed the divestiture of assets relating to its Enabling Services segment, namely its Endpoint Clinical (“Endpoint”) and Fortrea Patient Access (“FPA”) businesses, to Arsenal Capital Partners (“Arsenal”), a leading private equity firm specializing […]

DURHAM, N.C., June 04, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) a leading global contract research organization (“CRO”), today announced it has completed the divestiture of assets relating to its Enabling Services segment, namely its Endpoint Clinical (“Endpoint”) and Fortrea Patient Access (“FPA”) businesses, to Arsenal Capital Partners (“Arsenal”), a leading private equity firm specializing in building market-leading, technology-rich healthcare and industrial growth companies.

Endpoint and FPA provide best-in-class Randomization and Trial Supply Management (RTSM) and patient access solutions respectively. They both represent strategically differentiated entry points within the pharmaceutical services value chain, where Arsenal holds significant domain, scientific and technical knowledge.

Arsenal has appointed Sam Osman, former president of Fortrea’s Enabling Services segment, to serve as chief executive officer of the new entities, and Raymond (“Ray”) H. Hill, an operating partner within Arsenal’s healthcare team, will serve as chairman of the board.

“Endpoint and FPA are distinctly positioned to support the patient journey across clinical trials and through access to novel therapeutics after approval,” said Sam Osman, chief executive officer of Endpoint and FPA. “With Arsenal as our partner, I am confident that both our businesses and our teams will benefit from accelerated growth opportunities as well as investment and executive focus, resulting in enhanced capabilities and solutions for customers.”

“The successful closing of this transaction is a testament to the caliber of the teams involved, who have planned a smooth transition for colleagues, customers and the patients we serve,” said Fortrea Chairman and CEO Tom Pike. “This transaction enables both organizations to focus their leadership and resources on delivering optimal solutions for our customers. As previously disclosed, the net proceeds from this divestiture will be used to reduce a portion of Fortrea’s overall debt structure. As a pure-play clinical CRO, Fortrea remains committed to our mission of delivering solutions that bring life-changing treatments to patients faster.”

Ray Hill, an operating partner of Arsenal and chairman of the board for Endpoint and FPA, said, “I am incredibly excited to be a part of Endpoint and FPA’s next chapter. I look forward to working with the management team in building a strategically important company that provides data-driven solutions for patients.”

Endpoint Clinical
Endpoint operates in the high growth eClinical market as a leading provider of Randomization and Trial Supply Management (RTSM) solutions to biopharmaceutical and CRO customers with expertise in serving complex and late-stage clinical trials. For more than 15 years, Endpoint has had a successful track record of effectively supporting more than 1,750 clinical trials involving 875,000 patients across 90 countries and has cultivated a blue-chip customer base and nurtured long-standing strategic relationships.

Fortrea Patient Access
Fortrea Patient Access is a scaled leader in the HUB services and patient access market, serving the biopharmaceutical industry with comprehensive patient support, product access, affordability and adherence solutions for more than 30 years. Further advanced by its recently expanded non-commercial specialty pharmacy, FortreaRx™, to support enhanced distribution of cold-chain and ambient free goods products, Fortrea Patient Access is committed to driving patient outcomes and improving healthcare accessibility through its extensive experience while currently supporting more than 2.5 million patients and over 100 unique brands across more than 25 disease indications.

About Arsenal Capital Partners
Arsenal Capital Partners is a leading private equity investment firm that specializes in building market-leading industrial growth and healthcare companies. Since its inception in 2000, Arsenal has raised institutional equity investment funds totaling over $10 billion, completed more than 300 platform and add-on acquisitions, and achieved more than 35 realizations. The firm works with management teams to build strategically important companies with leading market positions, high growth and high value-add.  For more information, visit www.arsenalcapital.com.

About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, including the timing of the use of net proceeds to repay a portion of the Company’s outstanding debt. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “guidance,” “expect,” “assume,” “anticipate,” “intend,” “plan,” “forecast,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results could differ materially from these forward-looking statements due to a number of factors, including, but not limited to factors described from time to time in documents that the Company files with the SEC. For a further discussion of the risks relating to the Company’s business, see the “Risk Factors” Section of the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”), as such risk factors may be amended or updated from time to time in the Company’s subsequent periodic and other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included or incorporated by reference in the Company’s filings with the SEC. All forward-looking statements are made only as of the date of this release, and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward-looking statements to reflect future events or developments.

Fortrea Contacts:
Hima Inguva (Investors) – 877-495-0816, hima.inguva@fortrea.com
Sue Zaranek (Media) – 919-943-5422, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com

Arsenal Contact:

Ellen Pavlovsky – epavlovsky@arsenalcapital.com         

GlobeNewswire Distribution ID 9147983

Nyxoah to Participate in the Jefferies Global Healthcare Conference

Mont-Saint-Guibert, Belgium – June 3, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Jefferies Global Healthcare Conference, which takes […]

Mont-Saint-Guibert, Belgium – June 3, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Jefferies Global Healthcare Conference, which takes place June 5 – 6, 2024 in New York.

Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate presentation on Wednesday, June 5, 2024, at 7:30am ET. A webcast of the presentation will be available in the Events section of Nyxoah’s Investor Relations website. The Company will be available for 1×1 meetings with institutional investors.

Nyxoah’s Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com

Attachment

GlobeNewswire Distribution ID 1000964374

Information on the total number of voting rights and shares

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 3, 2024, 10:15 pm CET / 4:15 pm ET –In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.  Share capital: EUR 5,902,793.43  Total number […]

REGULATED INFORMATION

Information on the total number of voting rights and shares

Mont-Saint-Guibert (Belgium), June 3, 2024, 10:15 pm CET / 4:15 pm ET –In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.

  •  Share capital: EUR 5,902,793.43
  •  Total number of securities carrying voting rights: 34,360,390 (all ordinary shares)
  •  Total number of voting rights (= denominator): 34,360,390 (all relating to ordinary shares)
  •  Number of rights to subscribe to securities carrying voting rights not yet issued:
    •  100 “2018 ESOP Warrants” issued on December 12, 2018, entitling their holders to subscribe to a total number of 50,000 securities carrying voting rights (all ordinary shares);
    •  400,500 “2020 ESOP Warrants” issued on February 21, 2020, entitling their holders to subscribe to a total number of 400,500 securities carrying voting rights (all ordinary shares); and
    •  1,070,500 “2021 ESOP Warrants” issued on September 8, 2021, entitling their holders to subscribe to a total number of 1,070,500 securities carrying voting rights (all ordinary shares); and
    •  700,000 “2022 ESOP Warrants” issued on December 28, 2022, entitling their holders to subscribe to a total number of 700,000 securities carrying voting rights (all ordinary shares).

Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com

Attachment

GlobeNewswire Distribution ID 1000964376

Publication relating to transparency notifications

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), June 3, 2024, 10.05pm CET / 4.05pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received four transparency notifications as detailed below. FMR LLC On May 30, 2024, Nyxoah received a transparency notification from FMR LLC […]

REGULATED INFORMATION

Publication relating to transparency notifications

Mont-Saint-Guibert (Belgium), June 3, 2024, 10.05pm CET / 4.05pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received four transparency notifications as detailed below.

FMR LLC

On May 30, 2024, Nyxoah received a transparency notification from FMR LLC following the crossing above the 3% threshold on May 28, 2024. As of such date, FMR LLC (together with its controlled undertakings) held 1,698,402 voting rights, consisting of 1,613,888 shares and 84,514 equivalent financial instruments, representing 4.99% of the total number of voting rights on May 28, 2024 (34,060,390).

The notification dated May 30, 2024 contains the following information:

    •  Reason for the notification: acquisition or disposal of voting securities or voting rights
    •  Notification by: a parent undertaking or a controlling person
    •  Persons subject to the notification requirement: FMR LLC (with address at The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware, 19801, U.S.A.)
    •  Date on which the threshold was crossed: May 28, 2024
    •  Threshold that is crossed: 3%
    •  Denominator: 34,060,390
    •  Notified details:
A) Voting rights Previous notification After the transaction
# of voting rights # of voting rights % of voting rights
Holders of voting rights Linked to securities Not linked to the securities Linked to securities Not linked to the securities
FMR LLC 0 0 0.00%
FIAM LLC 0 258 0.00%
Fidelity Management & Research Company LLC 0 1,613,630 4.74%
Subtotal   1,613,888   4.74%  
TOTAL 1,613,888 0 4.74% 0.00%
B) Equivalent financial instruments After the transaction
Holders of equivalent financial instruments Type of financial instrument Expiration date Exercise period or date # of voting rights that may be acquired if the instrument is exercised % of voting rights Settlement
Fidelity Management & Research Company LLC Stock Loan 84,514 0.25% physical
TOTAL     84,514 0.25%  
TOTAL (A & B) # of voting rights % of voting rights  
      1,698,402 4.99%  
    •  Full chain of controlled undertakings through which the holding is effectively held: FIAM LLC is controlled by FIAM Holdings LLC. FIAM Holdings LLC, Fidelity Management & Research Company LLC are controlled by FMR LLC. FMR LLC is not a controlled undertaking.
    •  Additional information: The holdings attributed to the entities mentioned above arise from holdings of various undertakings for collective investment that are managed by FIAM LLC, Fidelity Management & Research Company LLC, each of which are entities that are subsidiaries of and controlled by FMR LLC. The entities mentioned above are the discretionary investment managers and exercise the voting rights at their discretion in the absence of specific instructions.

BlackRock, Inc.

On June 3, 2024, Nyxoah received a transparency notification from BlackRock, Inc. following the crossing above the 3% threshold on May 28, 2024. As of such date, BlackRock, Inc. (together with its controlled undertakings) held 1,116,429 voting rights, consisting of 1,097,929 shares and 18,500 equivalent financial instruments, representing 3.28% of the total number of voting rights on May 28, 2024 (34,060,390).

The notification dated May 29, 2024 contains the following information:

    •  Reason for the notification: acquisition or disposal of voting securities or voting rights
    •  Notification by: a parent undertaking or a controlling person
    •  Persons subject to the notification requirement:
      •  BlackRock, Inc. (with address at 50 Hudson Yards, New York, NY, 10001, U.S.A.)
      •  BlackRock Advisors, LLC (with address at 50 Hudson Yards, New York, NY, 10001, U.S.A.)
      •  BlackRock Fund Advisors (with address at 400 Howard Street, San Francisco, CA, 94105, U.S.A.)
      •  BlackRock Investment Management (UK) Limited (with address at 12 Throgmorton Avenue, London, EC2N 2DL, U.K.)
      •  BlackRock Investment Management, LLC (with address at 1 University Square Drive, Princeton, NJ, 8540, U.S.A.)
    •  Date on which the threshold was crossed: May 28, 2024
    •  Threshold that is crossed: 3%
    •  Denominator: 34,060,390
    •  Notified details:
A) Voting rights Previous notification After the transaction
# of voting rights # of voting rights % of voting rights
Holders of voting rights Linked to securities Not linked to the securities Linked to securities Not linked to the securities
BlackRock, Inc. 0 0.00%
BlackRock Advisors, LLC 1,071,561 3.15%
BlackRock Fund Advisors 46 0.00%
BlackRock Investment Management (UK) Limited 1,080 0.00%
BlackRock Investment Management, LLC 25,242 0.07%
Subtotal   1,097,929   3.22%  
TOTAL 1,097,929 0 3.22% 0.00%
B) Equivalent financial instruments After the transaction
Holders of equivalent financial instruments Type of financial instrument Expiration date Exercise period or date # of voting rights that may be acquired if the instrument is exercised % of voting rights Settlement
BlackRock Advisors, LLC Securities Lent 17,600 0.05% physical
BlackRock Fund Advisors Securities Lent 900 0.00% physical
TOTAL     18,500 0.05%  
TOTAL (A & B) # of voting rights % of voting rights  
      1,116,429 3.28%  
    •  Full chain of controlled undertakings through which the holding is effectively held:

BlackRock, Inc.
Trident Merger, LLC
BlackRock Investment Management, LLC

BlackRock, Inc.
BlackRock Holdco 2, Inc.
BlackRock Financial Management, Inc.
BlackRock International Holdings, Inc.
BR Jersey International Holdings L.P.
BlackRock Holdco 3, LLC
BlackRock Cayman 1 LP
BlackRock Cayman West Bay Finco Limited
BlackRock Cayman West Bay IV Limited
BlackRock Group Limited
BlackRock Finance Europe Limited
BlackRock Investment Management (UK) Limited

BlackRock, Inc.
BlackRock Holdco 2, Inc.
BlackRock Financial Management, Inc.
BlackRock Holdco 4, LLC
BlackRock Holdco 6, LLC
BlackRock Delaware Holdings Inc.
BlackRock Fund Advisors

BlackRock, Inc.
BlackRock Holdco 2, Inc.
BlackRock Financial Management, Inc.
BlackRock Capital Holdings, Inc.
BlackRock Advisors, LLC

    •  Additional information: The disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc. going above 3%. Additionally, total holdings for BlackRock, Inc. went above 3%. The disclosure obligation arose due to voting rights attached to shares for BlackRock Advisors, LLC going above 3%. Additionally, total holdings for BlackRock Advisors, LLC went above 3%.

Together Partnership

On June 3, 2024, Nyxoah received a transparency notification from Together Partnership following the passive crossing below the 10% threshold on May 28, 2024. As of such date, Together Partnership held 2,940,258 shares, representing 8.63% of the total number of voting rights on May 28, 2024 (34,060,390).

The notification dated June 3, 2024 contains the following information:

    •  Reason for the notification: passive crossing of a threshold
    •  Notification by: a person that notifies alone
    •  Persons subject to the notification requirement: Together Partnership (with address at Van Putlei 31, 2018 Antwerp, Belgium)
    •  Date on which the threshold was crossed: May 28, 2024
    •  Threshold that is crossed: 10%
    •  Denominator: 34,060,390
    •  Notified details:
A) Voting rights Previous notification After the transaction
# of voting rights # of voting rights % of voting rights
Holders of voting rights Linked to securities Not linked to the securities Linked to securities Not linked to the securities
Together Partnership 2,948,285 2,940,258 8.63%
TOTAL 2,940,258 0 8.63% 0.00%
    •  Full chain of controlled undertakings through which the holding is effectively held: Together Partnership is not a controlled entity.

Gilde Healthcare Holding BV and Gilde Healthcare III Management BV

On May 31, 2024, Nyxoah received a transparency notification from Gilde Healthcare Holding BV and Gilde Healthcare III Management BV following the passive crossing below the 10% threshold on May 28, 2024. As of such date, Gilde Healthcare Holding BV and Gilde Healthcare III Management BV (together with their controlled undertakings) held 2,936,890 shares, representing 8.62% of the total number of voting rights on May 28, 2024 (34,060,390).

The notification dated May 31, 2024 contains the following information:

    •  Reason for the notification: passive crossing of a threshold
    •  Notification by: a parent undertaking or a controlling person
    •  Persons subject to the notification requirement:
      •  Gilde Healthcare Holding BV (with address at Stadsplateau 36, 3521 AZ Utrecht, the Netherlands)
      •  Gilde Healthcare III Management BV (with address at Stadsplateau 36, 3521 AZ Utrecht, the Netherlands)
    •  Date on which the threshold was crossed: May 28, 2024
    •  Threshold that is crossed: 10%
    •  Denominator: 34,060,390
    •  Notified details:
A) Voting rights Previous notification After the transaction
# of voting rights # of voting rights % of voting rights
Holders of voting rights Linked to securities Not linked to the securities Linked to securities Not linked to the securities
Gilde Healthcare Holding BV 0 0 0.00%
Gilde Healthcare III Management BV 3,153,822 2,936,890 8.62%
Subtotal 3,153,822 2,936,890   8.62%  
TOTAL 2,936,890 0 8.62% 0.00%
    •  Full chain of controlled undertakings through which the holding is effectively held: Gilde Healthcare III Management BV is controlled by Gilde Healthcare Holding BV. Gilde Healthcare Holding BV is not a controlled entity.
    •  Additional information: Cooperatieve Gilde Healthcare III Sub-Holding UA and Cooperatieve Gilde Healthcare III Sub-Holding 2 UA hold the shares in Nyxoah. Gilde Healthcare III Management BV is the management company of these 2 entities, that in the absence of specific instructions can exercise the voting rights at its discretion.

Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com

Attachment

GlobeNewswire Distribution ID 1000964438

VIOLENT BORDER SHELLING BY ENEMY FORCES CAUSES WIDESPREAD DAMAGE IN SOUTHERN LEBANON OVERNIGHT

Violent border incursions by the Israeli enemy forces have caused significant damage to agricultural land, olive groves, and pine forests in the regions surrounding the Blue Line near the towns of Naquora, Al-Labouneh, Alma Al-Shaab, and Al-Bustan.

T…

Violent border incursions by the Israeli enemy forces have caused significant damage to agricultural land, olive groves, and pine forests in the regions surrounding the Blue Line near the towns of Naquora, Al-Labouneh, Alma Al-Shaab, and Al-Bustan. The attacks, which began late at night, resulted in the destruction of crops and trees, with firefighting teams from the Civil Defense quickly responded to extinguish the blazes. Despite the efforts of the Civil Defense, the enemy forces continued to launch heavy artillery shells and incendiary materials, targeting areas near the Blue Line in the western sector. The attacks also extended to the central sector, where the towns of Ayta Al-Shaab and Ramyeh were subjected to intermittent artillery fire, resulting in significant damage to properties. The bombardment continued throughout the night, with the enemy forces launching flares over border towns adjacent to the Blue Line, amidst reconnaissance flights over the districts of Tyre and Bint Jbeil. In the early m orning hours on Tuesday, the enemy forces opened fire with heavy machine guns towards the areas of Ayta Al-Shaab and Al-Dhaira. Source: National News Agency - Lebanon